FDA Grants Prime Medicine's PM359 RMAT Status, Expediting Review for CGD
Summary
Prime Medicine has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for PM359, its investigational therapy for Chronic Granulomatous Disease (CGD). This designation, based on positive Phase 1/2 clinical data, provides significant benefits including intensive FDA guidance, eligibility for rolling and priority review, and potential for accelerated approval. This substantially de-risks and accelerates the development pathway for a key pipeline asset, which is crucial for a company that recently reported Q1 2026 results with a 'going concern' warning. PM359 also holds Fast Track, Orphan Drug, and Rare Pediatric Disease Designations.
At the time of this announcement, PRME was trading at $3.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $583.4M. The 52-week trading range was $1.55 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.